



Medicines That Make a Difference®

Theravance Biopharma to Participate in an Upcoming Investor Conference

February 5, 2025

DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).

Webcast of the event may be accessed by visiting [Theravance.com](https://www.theravance.com), under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver *Medicines that Make a Difference*® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatrix company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:

investor_relations@theravance.com

650-808-4045

View original content to download multimedia: <https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302368408.html>

SOURCE Theravance Biopharma, Inc.